Key result
Intravenous neoadjuvant chemotherapy induced disparate histologic responses between primary tumors and metastases in 7 patients with metastatic osteosarcoma, suggesting tumor cell heterogeneity.
Why the study?
Does intravenous neoadjuvant chemotherapy induce uniform histologic responses in primary and metastatic osteosarcoma?
Population
7 patients with newly diagnosed metastatic osteosarcoma
Design
Case_series
Authors
Loading...
Hypothesis-generating for tumor heterogeneity in osteosarcoma; should not yet alter postoperative therapy decisions based solely on primary response.
Observational (n=7)
Does intravenous neoadjuvant chemotherapy induce uniform histologic responses in primary and metastatic osteosarcoma?
Histologic response to neoadjuvant chemotherapy varies between primary and metastatic osteosarcoma, suggesting tumor heterogeneity and challenging the practice of altering postoperative therapy based solely on primary tumor response.
Nachman et al. (1987) conducted an observational in Metastatic osteosarcoma (n=7). Intravenous neoadjuvant chemotherapy was evaluated on Histologic response. Intravenous neoadjuvant chemotherapy induced disparate histologic responses between primary tumors and metastases in 7 patients with metastatic osteosarcoma, suggesting tumor cell heterogeneity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: